ALZHEIMER’S BREAKTHROUGH: huge opportunity (and $$$) ahead if FDA grants urgent approval

The results will take your breath away July 30, 2019 "The last time something like this happened, investors made a quick 5,622%" Dear  Reader, I have something HUGE to share with you. An explosive combination of forces could hand you the biggest fortune of your life. If you act immediately. You see: In the world of biotechnology, the HOLY GRAIL for investors happens when a tiny, unknown company receives what's called a "Breakthrough Therapy Designation" during clinical trials. As you can imagine, it's very rare for the government to issue one of these Breakthrough Therapy Designations. And it's even rarer for such a breakthrough to be made by a small, little-known company. Yet when it happens fortunes are made – FAST. The last time it happened with a small-cap company like this, it was for a Hepatitis C treatment called Sovaldi… Investors who got in before the announcement pocketed a quick 5,622%. Today, I'm writing to you because a trusted colleague of mine is convinced it's about to happen again – with a breakthrough against the most terrifying disease of them all – Alzheimer's. If it happens, hang on tight. Investors who stake their claim in time could stand to make as much as 6,231%. The details are right here. Please read this immediately. Once it happens, it'll be too late. Click here now to get more details. Sincerely, Doug Hill Publisher, Gilder Daily Prophecy P.S. There's another company that's received one of these Breakthrough Therapy Designations. It's called Celgene. Perhaps you've heard of it. Today, it's a mega-billion-dollar leader in the battle against cancer. But before receiving its Breakthrough Therapy Designation shares of Celgene's stock traded for just 45 cents each. If you had invested back then, before it became a breakthrough company, you could've gone on to pocket a staggering 32,460% when all was said and done. Don't miss out again. Click here now. To end your Gilder's Daily Prophecy e-mail subscription and associated external offers sent from Gilder's Daily Prophecy, click here to unsubscribe. Gilder's Daily Prophecy is committed to protecting and respecting your privacy. Please read our Privacy Statement. Gilder Press, a division of Laissez Faire Books, LLC. 808 Saint Paul Street, Baltimore MD 21202. Nothing in this e-mail should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after online publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. © 2019 Gilder Press, a division of Laissez Faire Books, LLC. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Gilder Press, a division of Laissez Faire Books, LLC.